CN102961444A - Compound preparation for treating rhinosinusitis - Google Patents
Compound preparation for treating rhinosinusitis Download PDFInfo
- Publication number
- CN102961444A CN102961444A CN2012105431936A CN201210543193A CN102961444A CN 102961444 A CN102961444 A CN 102961444A CN 2012105431936 A CN2012105431936 A CN 2012105431936A CN 201210543193 A CN201210543193 A CN 201210543193A CN 102961444 A CN102961444 A CN 102961444A
- Authority
- CN
- China
- Prior art keywords
- parts
- compound preparation
- water
- decocting
- echinacea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a Chinese patent medicine compound preparation and particularly relates to a compound preparation for treating rhinosinusitis. The compound preparation is characterized by containing the water extract and decoction of fresh and mature fig, arborvitae tops, echinacea, baikal skullcap root, cocklebur fruit and liquorice, then ethanol precipitation is carried out, the supernatant liquid is taken and concentrated into clear paste, and the clear paste, sucrose and dextrin are uniformly mixed and then dried to be prepared into tablets or particles. The compound preparation provided by the invention has the functions of clearing away heat and toxic material, reducing swelling and alleviating pain, expelling wind and removing dampness, purging fire for removing toxin, promoting blood circulation and arresting bleeding, enhancing the immunity and resistance of the organism, improving symptoms and promoting nasal cavity and nasal sinus mucosa functions, and does not have toxic and side effects. Clinical applications prove that the compound preparation provided by the invention has obvious curative effects on postoperative recovery of acute and chronic rhinitis, paranasal sinusitis, rhinopharyngitis and nose and sinus parts, adjuvant therapy of malignant tumors at the parts and especially postoperative radiotherapy of patients, and has the obvious advantages of good performance, easiness in preparation, low cost, no toxic and side effects and the like.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine compound preparation, specifically a kind for the treatment of nose that has no side effect-sinusitis compound preparation.
Background technology
As everyone knows, rhinitis and sinusitis sickness rate are very high, are the diseases associated with inflammation of nasal cavity and sinus mucosa, and both are many to exist simultaneously, so be also referred to as nose-sinusitis, sickness rate accounts for about 15% of systemic disease, be nose section clinical in one of modal disease.Such as untimely treatment, often cause pathological changes and the general complication of adjacent organs, as: inflammation, meningitis, encephalitis etc. in acute and chronic otitis media, pharyngitis, tracheitis, the infection of socket of the eye week or the socket of the eye, if the inflammation whole body involves complication such as can causing myocarditis, rheumatic fever, urinary system infection.Antibiotic anti-inflammation and local glucocorticoid treatment are adopted in the home and abroad more at present, and drug side effect is larger, easily causes the whole body complication; Cure the symptoms, not the disease, relapse rate is high, and side effect is large.
In addition, behind nasal cavity and the operation on nasal sinus, because operation wound heals slower, and Chang Yinwei localized bacterial infection and affect wound healing at present, can only be used antibiotic therapy clinically, to prevent or to control inflammation, both increased patient economy burden, easily cause again untoward reaction.
Summary of the invention
[0003] the present invention overcomes the defective that exists in existing nasal cavity and the disease of accessory sinus treatment technology means, a kind of heat-clearing and toxic substances removing that has is proposed, dispel the wind have one's ideas straightened out, the eliminating stagnation blood stasis dispelling, reducing swelling and alleviating pain, eliminating fire and detoxication, promotion nasal cavity and the effects such as the reparation of sinus mucosa function and healing, and the treatment that has no side effect nose-sinusitis compound preparation.
The present invention can reach by following measure.
A kind of nose-sinusitis compound preparation for the treatment of is characterized in that technique is as follows:
Step 1, get respectively by weight Cacumen Platycladi 10-20 part, Echinacea 10-20 part, Radix Scutellariae 5-15 part, Fructus Xanthii 3-7 part, Radix Glycyrrhizae 2-5 part is carried out preorder and is processed, preorder is processed and is comprised that the water that adds the 40-50 weight portion is with Cacumen Platycladi, Echinacea, Radix Scutellariae, Fructus Xanthii and Radix Glycyrrhizae infusion get water extraction liquid after 3-4 hour, again to Cacumen Platycladi, Echinacea, Radix Scutellariae, the Fructus Fici 40-60 part that adds fresh maturation in Fructus Xanthii and the Radix Glycyrrhizae, water 10-20 part decocted 2 hours, get 20 parts of the first decocting liquids, adding water 10-20 part decocted 1 hour again, get 15 parts of the second decocting liquids, adding water 10-20 part decocted 0.5 hour again, get 10 parts of the 3rd decocting liquids
Step 2, resulting water extraction liquid, the first decocting liquid, the second decocting liquid and the 3rd decocting liquid are merged, concentrate after the merging, get 20-30 part concentrated solution,
Step 3, add in the concentrated solution qdx 70%-75% ethanol and stir, then leave standstill and get supernatant and be condensed into clear paste after precipitating in 24 hours,
Step 4, respectively 1 part of qinghuo reagent, 3 parts of sucrose, 1 part of mix homogeneously of dextrin of 1:3:1 are by weight again made tablet or the granule of 0.5g dosage after drying is processed.
Fructus Fici of the present invention contains 18 seed amino acids (10 kinds essential for human body institute) and multivitamin and mineral, and have to make eye bright and promote the production of body fluid, anti-inflammation detumescence, the drug effects such as spleen invigorating pain relieving, Fructus Fici contains anticancer active constituent, its Main Ingredients and Appearance comprises benzaldehyde, the furocoumarin lactone, Psoralen, the materials such as bergapton, show that after deliberation it can improve the genesis of body immunity and energy anticancer, simultaneously, healthy body cell is not caused any infringement, in addition, show after deliberation Fructus Fici, particularly contain a large amount of citric acids in the Fructus Fici of fresh maturation, Fumaric acid, succinic acid, malic acid, the third acetic acid, oxalic acid, the materials such as quininic acid, has the merit of anti-inflammation detumescence, so have the effect of good sharp anti-inflammation detumescence.
The main active of Echinacea is polyphenol, caffeic acid derivant, inulin and polysaccharide etc., has immunostimulation, wherein inulin can play a role by increasing granulocyte and leukocytic number, can improve mononuclear cell and produce bacteriolysis with the chemotaxis of neutral virus.Polysaccharide partly makes the Hydrocarbon receptor of T lymphocyte and Macrophage Surface produce immunostimulation, can increase the phagocytic activity of macrophage, and stimulating expression of macrophage increases the number of tumor necrosis factor, interferon, interleukin 8 number; Echinacea crude polysaccharides (EPS) but the obvious stimulation macrophage kills and wounds the activity of P815 oncocyte, and can destroy tumor cell.The caffeic acid derivant can increase the macrophage phagocytic ability.Echinacea can suppress the effect of hyaluronidase (hyaluronidase) in addition, stimulate growth and the glucamine Enzyme Production of fibroblast, produce the effect of cortex ketone, promote the secretion of adrenocortical hormone, upgrade and anti-sense bacterium and antiviral effect so have tissue.
Cacumen Platycladi contains volatile oil, and main component is α-absinthol, thujene, fenchone etc. in the oil, also contains the trace element such as potassium, sodium, nitrogen, phosphorus, calcium, magnesium, manganese and zinc in the leaf.α-absinthol, thujene, fenchone etc. can assign to bring into play antiinflammatory action by the activity of inhibition 5-lipoxygenase and the one-tenth of Cycloxygenase, and staphylococcus aureus, micrococcus catarrhalis, dysentery bacterium, Bacillus typhi, diphtheria corynebacterium etc. are all had inhibitory action; Its active ingredient of meletin and tannin can obviously shorten bleeding time and clotting time, have anastalsis.
Fructus Xanthii contains xanthostrumarin, resin and fatty oil, alkaloid, vitamin C and pigment etc.Staphylococcus aureus, group B streptococcus, streptococcus pneumoniae there are certain inhibitory action, and antifungic action is arranged.Can play in addition loose wind dehumidifying, the effect of understand things pain-stopping.
Scutellariae,radix contains flavone compound (baicalin and neobaicalein etc.), to dysentery bacterium, Bacillus typhi, Salmonella paratyphi, vibrio cholera, escherichia coli, Bacillus proteus, bacillus pyocyaneus, staphylococcus, hemolytic vessel used to hold grain at the imperial sacrifice coccus (a, B), Diplococcus pneumoniae, meningococcus, diphtheria corynebacterium etc. is had inhibitory action.Have simultaneously antifungal, antiviral, antiallergic action and antitumaous effect
Radix Glycyrrhizae has antiinflammatory, anti-allergic effects; can protect gastrointestinal mucosal and the tunica mucosa tracheae of inflammation; simultaneously some poisonous substance there is the Detoxication of similar glucuronic acid; in addition; Radix Glycyrrhizae can also have inhibitory action to the gastroxia that histamine causes, and the effect of antiacid gentle and gastrointestinal smooth muscle spasm is arranged.
The present invention proves through clinical practice, to acute and chronic rhinitis, nasal sinusitis, nasopharyngitis, the postoperative recovery of nose and nasal sinuses position, and the auxiliary treatment of above-mentioned position malignant tumor, especially postoperation radiotherapy patient, evident in efficacy, has heat-clearing and toxic substances removing, the eliminating stagnation blood stasis dispelling, reducing swelling and alleviating pain, loose wind dehumidifying, understand things pain-stopping, eliminating fire and detoxication, promoting blood circulation and hemostasis, enhancing human body immunity power and resistance, improve symptom, shorten the course of disease, promote the function that tissue injury repairs fast, and it is good to have performance, aboundresources, make easily, cost is lower, the remarkable advantage such as have no side effect.
The specific embodiment
The invention will be further described below in conjunction with embodiment.
Embodiment 1, and a kind of nose-sinusitis compound preparation for the treatment of is characterized in that technique is as follows:
Step 1, get respectively by weight 10 parts of Cacumen Platycladis, 10 parts of Echinaceas, 5 parts of Radix Scutellariaes, 3 parts of Fructus Xanthii, 2 parts in Radix Glycyrrhizae carries out preorder and processes, preorder is processed and is comprised that the water that adds 40 weight portions is with Cacumen Platycladi, Echinacea, Radix Scutellariae, Fructus Xanthii and Radix Glycyrrhizae infusion get water extraction liquid after 3 hours, again to Cacumen Platycladi, Echinacea, Radix Scutellariae, the Fructus Fici 40 that adds fresh maturation in Fructus Xanthii and the Radix Glycyrrhizae, 10 parts of decoctions of water 2 hours, get 20 parts of the first decocting liquids, adding 10 parts in water decocted 1 hour again, get 15 parts of the second decocting liquids, adding 10 parts in water decocted 0.5 hour again, get 10 parts of the 3rd decocting liquids
Step 2, resulting water extraction liquid, the first decocting liquid, the second decocting liquid and the 3rd decocting liquid are merged, concentrate after the merging, get 20 parts of concentrated solutions,
Step 3 adds 70% ethanol of qdx in the concentrated solution and stirs, then leaves standstill to get supernatant and be condensed into clear paste after precipitating in 24 hours,
Step 4, respectively 1 part of qinghuo reagent, 3 parts of sucrose, 1 part of mix homogeneously of dextrin of 1:3:1 are by weight again made tablet or the granule of 0.5g dosage after drying is processed.
Embodiment 2, and a kind of nose-sinusitis compound preparation for the treatment of is characterized in that technique is as follows:
Step 1, get respectively by weight 20 parts of Cacumen Platycladis, 20 parts of Echinaceas, 15 parts of Radix Scutellariaes, 7 parts of Fructus Xanthii, 5 parts in Radix Glycyrrhizae carries out preorder and processes, preorder is processed and is comprised that the water that adds 50 weight portions is with Cacumen Platycladi, Echinacea, Radix Scutellariae, Fructus Xanthii and Radix Glycyrrhizae infusion get water extraction liquid after 4 hours, again to Cacumen Platycladi, Echinacea, Radix Scutellariae, 60 parts of Fructus Ficis that add fresh maturation in Fructus Xanthii and the Radix Glycyrrhizae, water 10-20 part decocted 2 hours, get 20 parts of the first decocting liquids, adding 20 parts in water decocted 1 hour again, get 15 parts of the second decocting liquids, adding 20 parts in water decocted 0.5 hour again, get 10 parts of the 3rd decocting liquids
Step 2, resulting water extraction liquid, the first decocting liquid, the second decocting liquid and the 3rd decocting liquid are merged, concentrate after the merging, get 30 parts of concentrated solutions,
Step 3 adds 75% ethanol of qdx in the concentrated solution and stirs, then leaves standstill to get supernatant and be condensed into clear paste after precipitating in 24 hours,
Step 4, respectively 1 part of qinghuo reagent, 3 parts of sucrose, 1 part of mix homogeneously of dextrin of 1:3:1 are by weight again made tablet or the granule of 0.5g dosage after drying is processed.
Embodiment 3, and a kind of nose-sinusitis compound preparation for the treatment of is characterized in that technique is as follows:
Step 1, get respectively by weight 20 parts of Cacumen Platycladis, 10 parts of Echinaceas, 15 parts of Radix Scutellariaes, 3 parts of Fructus Xanthii, 5 parts in Radix Glycyrrhizae carries out preorder and processes, preorder is processed and is comprised that the water that adds 40 weight portions is with Cacumen Platycladi, Echinacea, Radix Scutellariae, Fructus Xanthii and Radix Glycyrrhizae infusion get water extraction liquid after 3-4 hour, again to Cacumen Platycladi, Echinacea, Radix Scutellariae, 60 parts of Fructus Ficis that add fresh maturation in Fructus Xanthii and the Radix Glycyrrhizae, 10 parts of decoctions of water 2 hours, get 20 parts of the first decocting liquids, adding 20 parts in water decocted 1 hour again, get 15 parts of the second decocting liquids, adding 20 parts in water decocted 0.5 hour again, get 10 parts of the 3rd decocting liquids
Step 2, resulting water extraction liquid, the first decocting liquid, the second decocting liquid and the 3rd decocting liquid are merged, concentrate after the merging, get 30 parts of concentrated solutions,
Step 3 adds 70% ethanol of qdx in the concentrated solution and stirs, then leaves standstill to get supernatant and be condensed into clear paste after precipitating in 24 hours,
Step 4, respectively 1 part of qinghuo reagent, 3 parts of sucrose, 1 part of mix homogeneously of dextrin of 1:3:1 are by weight again made the tablet of 0.5g dosage after drying is processed.
Embodiment 4, and a kind of nose-sinusitis compound preparation for the treatment of is characterized in that technique is as follows:
Step 1, get respectively by weight 20 parts of Cacumen Platycladis, 10 parts of Echinaceas, 5 parts of Radix Scutellariaes, 7 parts of Fructus Xanthii, 2 parts in Radix Glycyrrhizae carries out preorder and processes, preorder is processed and is comprised that the water that adds the 40-50 weight portion is with Cacumen Platycladi, Echinacea, Radix Scutellariae, Fructus Xanthii and Radix Glycyrrhizae infusion get water extraction liquid after 3-4 hour, again to Cacumen Platycladi, Echinacea, Radix Scutellariae, 40 parts of Fructus Ficis that add fresh maturation in Fructus Xanthii and the Radix Glycyrrhizae, 20 parts of decoctions of water 2 hours, get 20 parts of the first decocting liquids, adding 10 parts in water decocted 1 hour again, get 15 parts of the second decocting liquids, adding water 10-20 part decocted 0.5 hour again, get 10 parts of the 3rd decocting liquids
Step 2, resulting water extraction liquid, the first decocting liquid, the second decocting liquid and the 3rd decocting liquid are merged, concentrate after the merging, get 20 parts of concentrated solutions,
Step 3 adds 70% ethanol of qdx in the concentrated solution and stirs, then leaves standstill to get supernatant and be condensed into clear paste after precipitating in 24 hours,
Step 4, respectively 1 part of qinghuo reagent, 3 parts of sucrose, 1 part of mix homogeneously of dextrin of 1:3:1 by weight again, granulation after drying is processed.
Embodiment 5, and a kind of nose-sinusitis compound preparation for the treatment of is characterized in that technique is as follows:
Step 1, get respectively by weight 15 parts of Cacumen Platycladis, 14 parts of Echinaceas, 10 parts of Radix Scutellariaes, 6 parts of Fructus Xanthii, 3 parts in Radix Glycyrrhizae carries out preorder and processes, preorder is processed and is comprised that the water that adds 45 weight portions is with Cacumen Platycladi, Echinacea, Radix Scutellariae, Fructus Xanthii and Radix Glycyrrhizae infusion get water extraction liquid after 3-4 hour, again to Cacumen Platycladi, Echinacea, Radix Scutellariae, 50 parts of Fructus Ficis that add fresh maturation in Fructus Xanthii and the Radix Glycyrrhizae, 15 parts of decoctions of water 2 hours, get 20 parts of the first decocting liquids, adding 25 parts in water decocted 1 hour again, get 15 parts of the second decocting liquids, adding 15 parts in water decocted 0.5 hour again, get 10 parts of the 3rd decocting liquids
Step 2, resulting water extraction liquid, the first decocting liquid, the second decocting liquid and the 3rd decocting liquid are merged, concentrate after the merging, get 25 parts of concentrated solutions,
Step 3 adds 72% ethanol of qdx in the concentrated solution and stirs, then leaves standstill to get supernatant and be condensed into clear paste after precipitating in 24 hours,
Step 4, respectively 1 part of qinghuo reagent, 3 parts of sucrose, 1 part of mix homogeneously of dextrin of 1:3:1 are by weight again made the tablet of 0.5g dosage after drying is processed.
The processing technology of the medicine that the present invention relates to adopts the traditional fabrication method, both can make tablet, also can make pill or other electuaries are taken, when making electuary, at first take raw material by said ratio, and mode is concocted to carry out that preorder is processed as processed etc., then carry out water extraction, namely decoct with water three times, each 1 hour, collecting decoction, and concentrate, after this add qdx ethanol, leave standstill and get supernatant concentration after precipitating in 24 hours and become cream, again qinghuo reagent and sucrose, dextrin mixes oven dry in the 1:3:1 ratio and makes tablet or granule, and it is for subsequent use to press every packing of 0.5g.
The present invention has carried out zoopery with regard to clinical effectiveness and adverse effect, and concrete condition is as follows:
To 20 of normal adult male rabbit, be divided at random two groups, the A group is experimental group, the B group is matched group.
The A group is fed continuous application 30 days every day by 0.4g/kg/;
The B group is fed by normal nursing program;
Observe respectively two groups of untoward reaction situations, any side effect and untoward reaction do not appear in the result, illustrate that this medicine is safe and effective.
Prove that through clinical practice the present invention is to pathogenic bacterium and viral acute and chronic rhinitis, acute and chronic nasal sinusitis, nasopharyngitis, acute and chronic pharyngitis, angina, the bronchitis that causes, esophagitis etc. have good curative effect; Can promote nasal cavity, paranasal sinus, nasopharynx and the healing of bottleneck throat wound after surgery; To nasal cavity, paranasal sinus, nasopharynx and bottleneck throat malignant tumor auxiliary treatment, also has good effect.The present invention adopts oral administering mode when clinical use, with tablet, pill and the each 2g of electuary form, treat for 2-3 time every day, and its concrete condition is as follows:
Select acute sinusitis 50 examples, chronic sinusitis 60 examples, patient's 50 examples behind acute and chronic pharyngitis 50 routine ulcerative stomatitis 20 examples, angina nosocomii 15 examples, nasal cavity and the operation on nasal sinus, total effective rate 98%, cure rate is more than 90%.
Patient's 50 examples play obvious antiinflammatory, detumescence behind nasal cavity and the operation on nasal sinus, the eliminating stagnation blood stasis dispelling, and the effect of reducing swelling and alleviating pain promotes immediate union and the reparation of wound mucosa.
The auxiliary treatment of nasal cavity, nasal sinuses and nasopharyngeal malignant disease patient 30 examples, can play and promotes wound immediate union and obvious analgesic effect at clinical observation March ~ 30 months.Wherein adjuvant chemotherapy 20 examples obviously alleviate the digestive tract side reaction, and appetite stimulator improves sleep, alleviates cancerous pain, and all oncosises are per capita without recurrent cases at present.
The present invention proves through clinical practice, to acute and chronic rhinitis, nasal sinusitis, nasopharyngitis, the postoperative recovery of nose and nasal sinuses position, and the auxiliary treatment of above-mentioned position malignant tumor, postoperation radiotherapy patient especially, evident in efficacy.Has heat-clearing and toxic substances removing, the eliminating stagnation blood stasis dispelling, reducing swelling and alleviating pain, loose wind dehumidifying, understand things pain-stopping, eliminating fire and detoxication, promoting blood circulation and hemostasis, enhancing human body immunity power and resistance, the symptom of improving, the course of disease that shortens, promotion nasal cavity and sinus mucosa function be the effects such as reparation and healing fast, and a kind of compound preparation for the treatment of nose-sinusitis that has no side effect.And have that good, the easy making of performance, cost are low, the remarkable advantage such as have no side effect.
Claims (1)
1. treat nose-sinusitis compound preparation for one kind, it is characterized in that technique is as follows:
Step 1, get respectively by weight Cacumen Platycladi 10-20 part, Echinacea 10-20 part, Radix Scutellariae 5-15 part, Fructus Xanthii 3-7 part, Radix Glycyrrhizae 2-5 part is carried out preorder and is processed, preorder is processed and is comprised that the water that adds the 40-50 weight portion is with Cacumen Platycladi, Echinacea, Radix Scutellariae, Fructus Xanthii and Radix Glycyrrhizae infusion get water extraction liquid after 3-4 hour, again to Cacumen Platycladi, Echinacea, Radix Scutellariae, the Fructus Fici 40-60 part that adds fresh maturation in Fructus Xanthii and the Radix Glycyrrhizae, water 10-20 part decocted 2 hours, get 20 parts of the first decocting liquids, adding water 10-20 part decocted 1 hour again, get 15 parts of the second decocting liquids, adding water 10-20 part decocted 0.5 hour again, get 10 parts of the 3rd decocting liquids
Step 2, resulting water extraction liquid, the first decocting liquid, the second decocting liquid and the 3rd decocting liquid are merged, concentrate after the merging, get 20-30 part concentrated solution,
Step 3, add in the concentrated solution qdx 70%-75% ethanol and stir, then leave standstill and get supernatant and be condensed into clear paste after precipitating in 24 hours,
Step 4, respectively 1 part of qinghuo reagent, 3 parts of sucrose, 1 part of mix homogeneously of dextrin of 1:3:1 are by weight again made tablet or the granule of 0.5g dosage after drying is processed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012105431936A CN102961444A (en) | 2012-12-16 | 2012-12-16 | Compound preparation for treating rhinosinusitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012105431936A CN102961444A (en) | 2012-12-16 | 2012-12-16 | Compound preparation for treating rhinosinusitis |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102961444A true CN102961444A (en) | 2013-03-13 |
Family
ID=47792063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012105431936A Pending CN102961444A (en) | 2012-12-16 | 2012-12-16 | Compound preparation for treating rhinosinusitis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102961444A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105395610A (en) * | 2015-12-09 | 2016-03-16 | 刘传新 | Preparation for treatment of rhinitis and production method thereof |
RU2657512C1 (en) * | 2017-07-18 | 2018-06-14 | Отия Варламович Сичинава | Agent for treatment of suppurative rhinosinusitis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004091638A1 (en) * | 2003-04-16 | 2004-10-28 | Lavender Hill Projects Pty Ltd | Herbal composition |
CN1915298A (en) * | 2006-08-25 | 2007-02-21 | 袁爱仙 | Medication of medical broth for treating acute nasosinusitis and preparation method |
CN102462830A (en) * | 2010-11-01 | 2012-05-23 | 付志华 | External application medical solution for treating rhinitis |
CN102813698A (en) * | 2011-06-08 | 2012-12-12 | 王守康 | Preparation method of siberian cocklebur fruit pill for treating running nose disease |
-
2012
- 2012-12-16 CN CN2012105431936A patent/CN102961444A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004091638A1 (en) * | 2003-04-16 | 2004-10-28 | Lavender Hill Projects Pty Ltd | Herbal composition |
CN1915298A (en) * | 2006-08-25 | 2007-02-21 | 袁爱仙 | Medication of medical broth for treating acute nasosinusitis and preparation method |
CN102462830A (en) * | 2010-11-01 | 2012-05-23 | 付志华 | External application medical solution for treating rhinitis |
CN102813698A (en) * | 2011-06-08 | 2012-12-12 | 王守康 | Preparation method of siberian cocklebur fruit pill for treating running nose disease |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105395610A (en) * | 2015-12-09 | 2016-03-16 | 刘传新 | Preparation for treatment of rhinitis and production method thereof |
RU2657512C1 (en) * | 2017-07-18 | 2018-06-14 | Отия Варламович Сичинава | Agent for treatment of suppurative rhinosinusitis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102961444A (en) | Compound preparation for treating rhinosinusitis | |
CN102228504A (en) | Formula of anticancer Chinese medicine and process for preparing products of anticancer Chinese medicine | |
CN100387291C (en) | Medicine for treating pulmonary tuberculosis | |
CN104288477A (en) | Traditional Chinese medicine preparation curing infantile asthma | |
RU2190419C1 (en) | Medicinal vegetable species "fitomaks" | |
CN103566312B (en) | Traditional Chinese medicine combination for treating loss of appetite of pigs | |
CN102784272B (en) | Traditional Chinese medicine application agent for preventing and treating tonsils and throat inflammation induced by respiratory tract infection, and preparation method thereof | |
CN102961661B (en) | Compound preparation for treating upper respiratory infection and tracheitis | |
CN102038747B (en) | Compound electuary for treating faucitis | |
CN105232849A (en) | Plaster for treating burns | |
CN114159536B (en) | Pharmaceutical composition, preparation method and application thereof | |
CN107375699A (en) | Treat the Chinese medicine of breast cancer | |
CN101011512A (en) | Medicine for treating digestive tract tumour and its preparing process | |
CN101461854B (en) | Colitis treating Chinese medicine preparation | |
CN105267748A (en) | Traditional Chinese medicine composition for treating dermatitis | |
CN1803172A (en) | Medicine for treating chronic atrophic gastritis and its preparation method | |
CN103860806B (en) | A kind ofly treat the medicament that postpartum, abnormal menstrual period | |
CN100364586C (en) | Medicine for treating digestive tract tumor and its preparation method | |
CN104435232B (en) | A kind of Chinese medicine composition for treating toothache | |
CN101194992B (en) | Plaster medicament for treating thrush of baby | |
CN102274292A (en) | Chinese medicine for treating gastric ulcer and duodenal ulcer | |
CN103495038A (en) | Traditional Chinese medicine formula treating gastroenteric ulcers | |
CN114010689A (en) | Medicine for treating respiratory tract disease and its preparing method | |
CN103083538A (en) | Drug for treating hypertension and preparation method of the drug | |
CN107243041A (en) | A kind of medicament and its preparation technology for canker sore |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130313 |